NASDAQ: QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

Core Viewpoint - The law firm Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws on behalf of investors of uniQure N.V. following a press release from the company regarding its investigational gene therapy AMT-130 for Huntington's disease [1]. Group 1 - On November 3, 2025, uniQure announced that the FDA informed the company that the data for AMT-130 did not provide sufficient evidence to support its Biologics License Application [1].